International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026
Adjunctive corticosteroids and mortality in non-HIV patients with Pneumocystis jirovecii pneumonia: A systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pu Jiaqi, Wu Shouquan, He Jian-Qing
Аннотация
BACKGROUND: The role of adjunctive corticosteroids in non-HIV PJP remains controversial.
METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) and observational studies comparing adjunctive corticosteroids plus standard antimicrobial therapy versus standard therapy alone in HIV-negative adults with PJP. We searched PubMed, Embase, Web of Science, and Cochrane Library from inception to December 19, 2025. The primary outcome was all-cause mortality. We performed meta-analyses using random-effects models, subgroup analyses by mortality timing, and sensitivity analyses.
RESULTS: Twenty studies (one RCT, 19 observational studies) involving 3816 patients were included. Among 2899 patients receiving corticosteroids, 756 died (26.1%), compared to 246 deaths among 917 controls (26.8%). The pooled analysis showed no significant association between adjunctive corticosteroids and all-cause mortality (odds ratio [OR] 1.10, 95% confidence interval [CI]: 0.86-1.41; P = 0.43; I² = 21%). Subgroup analyses for short-term (≤30-day) mortality (OR: 1.13, 95% CI: 0.78-1.63) and long-term (>30-day) mortality (OR: 1.36, 95% CI: 0.79-2.32) also demonstrated no significant benefit. Results were robust in sensitivity analyses.
CONCLUSION: Adjunctive corticosteroids were not associated with reduced mortality in non-HIV PJP. However, the overall certainty of evidence was very low. Based on current evidence, routine corticosteroid use is not supported, and these findings should be interpreted with caution. Future high-quality randomized trials are needed.
METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) and observational studies comparing adjunctive corticosteroids plus standard antimicrobial therapy versus standard therapy alone in HIV-negative adults with PJP. We searched PubMed, Embase, Web of Science, and Cochrane Library from inception to December 19, 2025. The primary outcome was all-cause mortality. We performed meta-analyses using random-effects models, subgroup analyses by mortality timing, and sensitivity analyses.
RESULTS: Twenty studies (one RCT, 19 observational studies) involving 3816 patients were included. Among 2899 patients receiving corticosteroids, 756 died (26.1%), compared to 246 deaths among 917 controls (26.8%). The pooled analysis showed no significant association between adjunctive corticosteroids and all-cause mortality (odds ratio [OR] 1.10, 95% confidence interval [CI]: 0.86-1.41; P = 0.43; I² = 21%). Subgroup analyses for short-term (≤30-day) mortality (OR: 1.13, 95% CI: 0.78-1.63) and long-term (>30-day) mortality (OR: 1.36, 95% CI: 0.79-2.32) also demonstrated no significant benefit. Results were robust in sensitivity analyses.
CONCLUSION: Adjunctive corticosteroids were not associated with reduced mortality in non-HIV PJP. However, the overall certainty of evidence was very low. Based on current evidence, routine corticosteroid use is not supported, and these findings should be interpreted with caution. Future high-quality randomized trials are needed.